Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

EME MariottiPKPrashant KapoorADAngela Dispenzieri

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals MRD negativity post ASCT influences progression-free survival in multiple myeloma patients with high-risk cytogenetics, indicating need for risk-adapted therapy.

Key Points

  • To evaluate the impact of measurable residual disease negativity on progression-free survival in multiple myeloma patients post-autologous stem cell transplantation.
  • Retrospective analysis of patients with newly diagnosed multiple myeloma who underwent ASCT
  • Patients categorized based on high-risk cytogenetic abnormalities and MRD status
  • Progression-free survival assessed using Kaplan–Meier methodology.
  • 386 patients achieved MRD negativity post-ASCT, 381 had cytogenetic data for analysis
  • Presence of certain high-risk cytogenetic abnormalities was associated with poorer progression-free survival
  • Patients with del(17p) and t(4;14) had significantly worse outcomes despite MRD negativity

Cite This Study

Mariotti et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d40ahttps://doi.org/10.1182/blood-2025-362
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma2024 · 13 citations
  2. 2Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  3. 3Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  4. 4Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma2026
  5. 5Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.2025